



#6

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In Re Application of : Shimon SLAVIN  
Serial No. : 10/005,747  
Filed : December 3, 2001  
For : IMMUNOTHERAPY OF CANCER WITH  
ALLOGENIC LYMPHOCYTES  
Art Unit : 1644  
Attorney Docket No. : **02/23156**

**REQUEST FOR CORRECTED FILING RECEIPT**

Director of the United States Patent and Trademark Office  
US Patent and Trademark Office  
Washington, D.C. 20231

Sir:

1. Attached is a copy of the official filing receipt received from the US Patent and Trademark Office in the above application. Issuance of a corrected filing receipt is respectfully requested.


2. Please add the following Priority data:

Con of 08/735,496 10/23/1996  
Con of 08/656,694 6/3/1996  
Con of 08/214,944 3/17/1994

Respectfully submitted,

Sol Sheinbein  
Registration No. 25,457

March 3, 2002  
Ramat Gan, Israel



UNITED STATES PATENT AND TRADEMARK OFFICE

JML  
16887D000151US

Page 1 of 2

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

JIDB

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
10/005,747	12/03/2001	1644	0.00	16887D-000151US	4	19	2

CONFIRMATION NO. 1863

20350  
TOWNSEND AND TOWNSEND AND CREW, LLP  
TWO EMBARCADERO CENTER  
EIGHTH FLOOR  
SAN FRANCISCO, CA 94111-3834

FILING RECEIPT



\*OC000000007262094\*

(d)

Date Mailed: 01/03/2002

02/23/56

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

**Applicant(s)**

Shimon Slavin, Jerusalem, ISRAEL;

**Domestic Priority data as claimed by applicant**

THIS APPLICATION IS A CON OF 09/310,325 05/12/1999

**Foreign Applications**

If Required, Foreign Filing License Granted 01/03/2002

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

**Title**

Immunotherapy of cancer with allogeneic lymphocytes

**Preliminary Class**

424

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).